Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China

The World Health Organization guidelines recommend lopinavir/ritonavir (LPV/r) as a second-line antiretroviral therapy (ART) for HIV-infected adults in middle-income and low-income countries as a protease inhibitor boost based on clinical trials; however, the real-world safety and efficacy remain un...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiaojie, Xu, Liumei, Sun, Lijun, Gao, Guiju, Cai, Weiping, Liu, Yanfen, Ding, Haibo, Wei, Hongxia, Ma, Ping, Wang, Min, Liu, Shuiqing, Chen, Yaokai, Chen, Xiaohong, Zhao, Qingxia, Yu, Jianhua, Song, Yuxia, Chen, Hui, Wu, Hao, Qin, Shanfang, Li, Linghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917650/
https://www.ncbi.nlm.nih.gov/pubmed/31920648
http://dx.doi.org/10.3389/fphar.2019.01455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917650/
https://www.ncbi.nlm.nih.gov/pubmed/31920648
http://dx.doi.org/10.3389/fphar.2019.01455

Ejemplares similares